ClinConnect ClinConnect Logo
Search / Trial NCT06884631

Metabolic Exercise Test Data Combined with Cardiac and Kidney Indexes (MECKI) Score Evolution: Identification of Cardiovascular Risk in Patients with Heart Failure

Launched by CENTRO CARDIOLOGICO MONZINO · Mar 18, 2025

Trial Information

Current as of April 23, 2025

Recruiting

Keywords

Prognosis Risk Score Heart Failure Cardiopulmonary Exercise Test Exercise

ClinConnect Summary

The MECKI trial is studying a new way to assess the risk of heart problems in patients with heart failure. Heart failure affects not just the heart but also other organs, making it important to consider various factors for a complete understanding of a patient's health. This trial aims to refine a scoring system called the MECKI score, which combines information from exercise tests and other health data to help predict the risk levels more accurately. By updating this score with new patient data and treatment approaches, the goal is to improve its effectiveness for different groups of patients.

To participate in the trial, individuals must be over 18 years old and have a history of heart failure with specific heart function measurements. Key factors include stable health conditions and having previously undergone an exercise test. Participants can expect to provide information about their health and potentially help improve how heart failure is managed in the future. Overall, this trial could lead to better risk assessments, helping doctors provide more personalized care for patients with heart failure.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • age \>18 past or present heart failure (NYHA functional class I-III, stage C of the ACC/AHA classification)
  • documentation of left ventricular systolic dysfunction (LVEF \<40%)
  • stable clinical conditions
  • previous or concomitant cardiopulmonary exercise test
  • Exclusion Criteria:
  • scheduled cardiovascular treatment
  • clinical unstable condition
  • History of pulmonary embolism, significant valvular disease, pericardial disease, severe COPD, exercise-induced angina, exercise-induced ECG changes, severe brady- or tachyarrhythmias, or the presence of comorbidities that interfere with exercise performance.

About Centro Cardiologico Monzino

Centro Cardiologico Monzino (CCM) is a leading cardiovascular research and treatment facility based in Milan, Italy, renowned for its commitment to advancing cardiac care through innovative clinical trials and cutting-edge research. Affiliated with the Italian Ministry of Health, CCM specializes in a comprehensive range of cardiovascular services, including diagnostics, interventional cardiology, and rehabilitation. The institution is dedicated to fostering collaboration among healthcare professionals, researchers, and patients to enhance the understanding of cardiovascular diseases and improve therapeutic outcomes. With a focus on translating scientific discoveries into clinical practice, CCM plays a pivotal role in shaping the future of cardiovascular medicine.

Locations

Milano, , Italy

Brescia, , Italy

Piacenza, , Italy

Roma, , Italy

Napoli, , Italy

Napoli, , Italy

Bergamo, , Italy

Brescia, , Italy

Roma, , Italy

Ancona, , Italy

San Donato Milanese, Milan, Italy

Trieste, , Italy

Milano, , Italy

Rome, , Italy

Foggia, , Italy

Bari, , Italy

Milano, , Italy

Milano, , Italy

Milano, , Italy

Milano, , Italy

Naples, , Italy

Palermo, , Italy

Pisa, , Italy

Rome, , Italy

Siena, , Italy

Siena, , Italy

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported